Clinical trial
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine…
NCT00216281 · Indiana University School of Medicine, Other · Terminated
Key facts
| NCT number | NCT00216281 |
|---|---|
| Title | Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia |
| Official title | Correlation of Phenotype, Genotype and Clinical Efficacy/Toxicity of Clozapine Augmented by Atomoxetine for Treatment Refractory Schizophrenia (CAPG Study) |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | Hoffmann-La Roche Industry Shekhar, Anantha M.D., Ph.D. |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Clozapine augmented with atomoxetine up to 40 mg or placebo |
| Enrollment | 126 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Sep 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Mar 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: